Evidence map›Paper›PMID 30922300›Full record

ArticleMicrobial cell factories2019

Metabolic engineering of Ashbya gossypii for deciphering the de novo biosynthesis of γ-lactones.

Rui Silva, Tatiana Q Aguiar, Eduardo Coelho, Alberto Jiménez, José Luis Revuelta, Lucília Domingues

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. New Promoters for Metabolic Engineering ofJournal of fungi (Basel, Switzerland) · 2021
    Article
  6. Article
  7. Sporulation inJournal of fungi (Basel, Switzerland) · 2020
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Rui SilvaCEB-Centre of Biological Engineering, University of Minho, 4710-057, Braga, Portugal.
Tatiana Q AguiarCEB-Centre of Biological Engineering, University of Minho, 4710-057, Braga, Portugal.
Eduardo CoelhoCEB-Centre of Biological Engineering, University of Minho, 4710-057, Braga, Portugal.
Alberto JiménezMetabolic Engineering Group, Department of Microbiology and Genetics, University of Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain.
José Luis RevueltaMetabolic Engineering Group, Department of Microbiology and Genetics, University of Salamanca, Campus Miguel de Unamuno, 37007, Salamanca, Spain.
Lucília DominguesCEB-Centre of Biological Engineering, University of Minho, 4710-057, Braga, Portugal. luciliad@deb.uminho.pt.ORCID http://orcid.org/0000-0003-1089-7627
University of Minho · PTUniversidad de Salamanca · ES

Funding

Consejería de Educación, Junta de Castilla y León SA016P17European Regional Development Fund NORTE-01-0145-FEDER-000004Fundação para a Ciência e a Tecnologia PD/BD/113812/2015Fundação para a Ciência e a Tecnologia POCI-01-0145-FEDER-006684Fundação para a Ciência e a Tecnologia UID/BIO/04469/2019Ministerio de Economía, Industria y Competitividad, Gobierno de España BIO2014-56930-PMinisterio de Economía, Industria y Competitividad, Gobierno de España BIO2017-88435-R
6 · The paper itself

Abstract

backgroundLactones are highly valuable cyclic esters of hydroxy fatty acids that find application as pure fragrances or as building blocks of speciality chemicals. While chemical synthesis often leads to undesired racemic mixtures, microbial production allows obtaining optically pure lactones. The production of a specific lactone by biotransformation depends on the supply of the corresponding hydroxy fatty acid, which has economic and industrial value similar to γ-lactones. Hence, the identification and exploration of microorganisms with the rare natural ability for de novo biosynthesis of lactones will contribute to the long-term sustainability of microbial production. In this study, the innate ability of Ashbya gossypii for de novo production of γ-lactones from glucose was evaluated and improved.

resultsCharacterization of the volatile organic compounds produced by nine strains of this industrial filamentous fungus in glucose-based medium revealed the noteworthy presence of seven chemically different γ-lactones. To decipher and understand the de novo biosynthesis of γ-lactones from glucose, we developed metabolic engineering strategies focused on the fatty acid biosynthesis and the β-oxidation pathways. Overexpression of AgDES589, encoding a desaturase for the conversion of oleic acid (C18:1) into linoleic acid (C18:2), and deletion of AgELO624, which encodes an elongase that catalyses the formation of C20:0 and C22:0 fatty acids, greatly increased the production of γ-lactones (up to 6.4-fold; (7.6 ± 0.8) × 10

conclusionsThis study demonstrates the potential of A. gossypii as a model and future platform for de novo biosynthesis of γ-lactones. By means of metabolic engineering, key enzymatic steps involved in their production were elucidated. Moreover, the combinatorial metabolic engineering strategies developed resulted in improved de novo biosynthesis of γ-decalactone. In sum, these proof-of-concept data revealed yet unknown metabolic and genetic determinants important for the future exploration of the de novo production of γ-lactones as an alternative to biotransformation processes.

Indexed as

LactonesEremotheciumFatty AcidsMetabolic EngineeringOxidation-ReductionVolatile Organic CompoundsFatty AcidsLactonesVolatile Organic CompoundsAshbya gossypiiDe novo biosynthesisFatty acid biosynthesisMetabolic engineeringVolatile organic compoundsβ-Oxidationγ-Lactones

Identifiers

PMID30922300
PMCPMC6437850
OpenAlexW2936934704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.